Skip to main content

Table 8 Most common adverse events (reported by ≥10% of patients), total and by dose at onset of AE, safety population (n = 60)

From: Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study

  Number (%) of patients
   Dose at onset
Preferred term Total 10 mg 20 mg 30, 35 mg 40, 45 mg 50 mg
Headache 21 (35.0) 10 (16.7) 6 (10.0) 5 (8.3) 1 (1.7) 3 (5.0)
Nausea 15 (25.0) 6 (10.0) 3 (5.0) 3 (5.0) 2 (3.3) 2 (3.3)
Diarrhoea 15 (25.0) 6 (10.0) 3 (5.0) 3 (5.0) 2 (3.3) 5 (8.3)
Nasopharyngitis 15 (25.0) 5 (8.3) 2 (3.3) 6 (10.0) 1 (1.7) 2 (3.3)
Hyperhidrosis 12 (20.0) 3 (5.0) 3 (5.0) 4 (6.7) 1 (1.7) 1 (1.7)
Upper respiratory tract infection 12 (20.0) 2 (3.3) 5 (8.3) 3 (5.0) 2 (3.3) 2 (3.3)
Fatigue 10 (16.7) 3 (5.0) 1 (1.7) 2 (3.3) 5 (8.3) 0 (0)
Dizziness 10 (16.7) 3 (5.0) 2 (3.3) 4 (6.7) 0 (0) 1 (1.7)
Vomiting 8 (13.3) 3 (5.0) 1 (1.7) 4 (6.7) 0 (0) 2 (3.3)
Abnormal dreams 6 (10.0) 2 (3.3) 0 (0) 3 (5.0) 1 (1.7) 1 (1.7)
Arthralgia 6 (10.0) 0 (0) 3 (5.0) 0 (0) 3 (5.0) 0 (0)
Back pain 6 (10.0) 0 (0) 2 (3.3) 2 (3.3) 1 (1.7) 1 (1.7)
Influenza like illness 6 (10.0) 1 (1.7) 1 (1.7) 1 (1.7) 1 (1.7) 3 (5.0)
Influenza 6 (10.0) 0 (0) 2 (3.3) 1 (1.7) 0 (0) 3 (5.0)
Lethargy 6 (10.0) 2 (3.3) 2 (3.3) 0 (0) 2 (3.3) 0 (0)
Oropharyngeal pain 6 (10.0) 0 (0) 2 (3.3) 2 (3.3) 1 (1.7) 1 (1.7)
Pain in extremity 6 (10.0) 0 (0) 2 (3.3) 3 (5.0) 2 (3.3) 0 (0)
Rash 6 (10.0) 2 (3.3) 2 (3.3) 0 (0) 1 (1.7) 2 (3.3)